financetom
Business
financetom
/
Business
/
Vallourec's core profit drops on lower tube prices in North America
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vallourec's core profit drops on lower tube prices in North America
Feb 26, 2025 11:01 PM

(Reuters) - French metallurgical group Vallourec reported a 23.6% drop in its fourth quarter core profit on Thursday, citing lower average selling prices in its North American tubes business.

Vallourec, which makes tubing for oil and gas, low-carbon energy and industrial markets, said its operating earnings before interest, taxes, depreciation and amortization (EBITDA) fell to 214 million euros ($224 million) in the final quarter of 2024.

($1 = 0.9555 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ovintiv Renews Buyback Program for 10% of Outstanding Shares
Ovintiv Renews Buyback Program for 10% of Outstanding Shares
Oct 2, 2024
05:44 PM EDT, 09/26/2024 (MT Newswires) -- Ovintiv ( OVV ) disclosed regulatory approvals late Thursday to renew its share buyback program to repurchase 10% of its public float as of Sept. 20. The program, which returns at least 50% of non-GAAP free cash flow to shareholders after base dividend, said the Toronto Stock Exchange accepted the renewal of its...
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
Oct 2, 2024
WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former executives for misleading claims about the results of Alzheimer's clinical trials. The misleading statements were made in September 2020 about the results of a phase two clinical trial for Cassava's purported drug treatment...
Mosaic Expected Q3 Sales Disruptions Due to Equipment Problems, Hurricanes
Mosaic Expected Q3 Sales Disruptions Due to Equipment Problems, Hurricanes
Oct 2, 2024
06:04 PM EDT, 09/26/2024 (MT Newswires) -- Mosaic (MOS) late Thursday said Q3 sales volumes of potash and phosphates would likely trail its prior forecasts due to production disruptions and other operational challenges at several facilities. The company is now expecting potash sales between 1.85 million to 2.05 million tonnes during Q3, down from its earlier guidance looking for 2.1...
US FDA approves Bristol Myers' schizophrenia drug
US FDA approves Bristol Myers' schizophrenia drug
Oct 2, 2024
(Corrects paragraph 1 to say U.S. FDA is news source, not Bristol Myers) Sept 26 (Reuters) - The U.S. FDA approved Bristol Myers Squibb's ( BMY ) schizophrenia drug on Thursday, providing patients with a treatment option that reduces symptoms of the mental disorder without common side effects, the health regulator said. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved